Format

Send to

Choose Destination
An Pediatr (Barc). 2014 Nov;81(5):328.e1-9. doi: 10.1016/j.anpedi.2014.03.011. Epub 2014 Apr 24.

[Consensus document on the clinical use of melatonin in children and adolescents with sleep-onset insomnia].

[Article in Spanish]

Author information

1
Asociación Española de Pediatría (AEP), Valencia, España. Electronic address: pinarboledasgonzalo@gmail.com.
2
Sociedad Española de Sueño (SES), Madrid, España.
3
Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP), Salamanca, España.
4
Sociedad Española de Medicina de la Adolescencia (SEMA), Madrid, España.
5
Sociedad de Psiquiatría Infantil (SPI), Tenerife, España.
6
Sociedad Española de Neurología Pediátrica (SENEP), Madrid, España.
7
Laboratorio de Cronobiología, Departamento de Fisiología, Universidad de Murcia, Murcia, España.

Abstract

Sleep problems are highly prevalent among our children and adolescents. Its treatment is mainly based on cognitive behavioural therapies and habit modification procedures. However, the use of sleep promoting drugs and substances is widespread without being supported by clinical guidelines. Exogenous melatonin is a neurohormone marketed as a nutritional supplement that is being increasingly used in the management of sleep problems, and with no control over its use. The consensus document is presented on the use of melatonin in sleep-onset insomnia prepared by representatives of the Spanish Paediatric Association, the Spanish Society of Sleep, the Spanish Society of Paediatric Outpatients and Primary Care, the Spanish Society for Adolescent Medicine, the Spanish Society of Child Psychiatry, and the Spanish Society of Paediatric Neurology.

KEYWORDS:

Insomnio de inicio; Melatonin; Melatonina; Retraso de fase; Sleep delay; Sleep-onset insomnia

Comment in

PMID:
24768501
DOI:
10.1016/j.anpedi.2014.03.011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center